Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank Disease ID
1 Acute myeloid leukemia 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
2 Acute myeloid leukemia 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
3 Acute myeloid leukemia 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
4 Acute myeloid leukemia 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
5 Adipocytokine signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
6 Adipocytokine signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
7 Adrenergic signaling in cardiomyocytes 💬
[2] ADRB1, ADRB2 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
8 Adrenergic signaling in cardiomyocytes 💬
[2] ADRB1, ADRB2 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
9 AGE-RAGE signaling pathway in diabetic complications 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
10 Alcoholism 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
11 Aldosterone-regulated sodium reabsorption 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
12 Alzheimer disease 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
13 Alzheimer disease 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
14 Alzheimer disease 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
15 Alzheimer disease 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
16 Amoebiasis 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
17 AMPK signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
18 AMPK signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
19 AMPK signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
20 Amyotrophic lateral sclerosis 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
21 Amyotrophic lateral sclerosis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
22 Apelin signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
23 Apelin signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
24 Apelin signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
25 Apoptosis 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
26 Apoptosis 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
27 Autophagy - animal 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
28 Autophagy - animal 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
29 Autophagy - animal 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
30 Autophagy - animal 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
31 Autophagy - other 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
32 Autophagy - other 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
33 Axon guidance 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
34 B cell receptor signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
35 B cell receptor signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
36 Bacterial invasion of epithelial cells 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
37 Bladder cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
38 Breast cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
39 Breast cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
40 Breast cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
41 Breast cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
42 C-type lectin receptor signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
43 Cadherin signaling 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
44 Calcium signaling pathway 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
45 Calcium signaling pathway 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
46 cAMP signaling pathway 💬
[2] ADRB1, ADRB2 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
47 cAMP signaling pathway 💬
[2] ADRB1, ADRB2 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
48 cAMP signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
49 cAMP signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
50 Carbohydrate digestion and absorption 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
51 Cellular senescence 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
52 Cellular senescence 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
53 Cellular senescence 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
54 Cellular senescence 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
55 Central carbon metabolism in cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
56 Central carbon metabolism in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
57 Central carbon metabolism in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
58 Central carbon metabolism in cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
59 cGMP-PKG signaling pathway 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
60 cGMP-PKG signaling pathway 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
61 cGMP-PKG signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
62 cGMP-PKG signaling pathway 💬
[1] PDE5A 💬 Sildenafil citrate 💬 Sildenafil [17]  6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬
63 cGMP-PKG signaling pathway 💬
[1] PDE5A 💬 Sildenafil 💬 Sildenafil [17]  6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬
64 Chagas disease 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
65 Chemical carcinogenesis - reactive oxygen species 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
66 Chemical carcinogenesis - reactive oxygen species 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
67 Chemical carcinogenesis - receptor activation 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
68 Chemical carcinogenesis - receptor activation 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
69 Chemical carcinogenesis - receptor activation 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
70 Chemical carcinogenesis - receptor activation 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
71 Chemical carcinogenesis - receptor activation 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
72 Chemical carcinogenesis - receptor activation 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
73 Chemokine signaling pathway 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
74 Chemokine signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
75 Choline metabolism in cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
76 Choline metabolism in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
77 Choline metabolism in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
78 Choline metabolism in cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
79 Cholinergic synapse 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
80 Cholinergic synapse 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
81 Chronic myeloid leukemia 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
82 Chronic myeloid leukemia 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
83 Colorectal cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
84 Colorectal cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
85 Colorectal cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
86 Colorectal cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
87 Coronavirus disease 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
88 Cushing syndrome 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
89 Diabetic cardiomyopathy 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
90 Diabetic cardiomyopathy 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
91 Diabetic cardiomyopathy 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
92 Dilated cardiomyopathy 💬
[1] ADRB1 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
93 Dilated cardiomyopathy 💬
[1] ADRB1 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
94 Efferocytosis 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
95 Endometrial cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
96 Endometrial cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
97 Epstein-Barr virus infection 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
98 ErbB signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
99 ErbB signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
100 ErbB signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
101 ErbB signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
102 Estrogen signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
103 Estrogen signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
104 Fc epsilon RI signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
105 Fc epsilon RI signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
106 Fc gamma R-mediated phagosome formation 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
107 Fc gamma R-mediated phagosome formation 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
108 Fluid shear stress and atherosclerosis 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
109 Focal adhesion 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
110 Focal adhesion 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
111 FoxO signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
112 FoxO signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
113 Gap junction 💬
[1] ADRB1 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
114 Gap junction 💬
[1] ADRB1 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
115 Gap junction 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
116 Gastric cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
117 Gastric cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
118 Gastric cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
119 Gastric cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
120 Glioma 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
121 Glioma 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
122 Glioma 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
123 Glioma 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
124 GnRH secretion 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
125 GnRH secretion 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
126 GnRH signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
127 Growth hormone synthesis, secretion and action 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
128 Growth hormone synthesis, secretion and action 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
129 Growth hormone synthesis, secretion and action 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
130 Growth hormone synthesis, secretion and action 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
131 Hepatitis B 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
132 Hepatitis B 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
133 Hepatitis C 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
134 Hepatitis C 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
135 Hepatocellular carcinoma 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
136 Hepatocellular carcinoma 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
137 Hepatocellular carcinoma 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
138 Hepatocellular carcinoma 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
139 Herpes simplex virus 1 infection 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
140 Herpes simplex virus 1 infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
141 Herpes simplex virus 1 infection 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
142 HIF-1 signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
143 HIF-1 signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
144 HIF-1 signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
145 HIF-1 signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
146 Hormone signaling 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
147 Hormone signaling 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
148 Hormone signaling 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
149 Human cytomegalovirus infection 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
150 Human cytomegalovirus infection 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
151 Human cytomegalovirus infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
152 Human cytomegalovirus infection 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
153 Human immunodeficiency virus 1 infection 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
154 Human immunodeficiency virus 1 infection 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
155 Human immunodeficiency virus 1 infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
156 Human immunodeficiency virus 1 infection 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
157 Human papillomavirus infection 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
158 Human papillomavirus infection 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
159 Human papillomavirus infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
160 Human papillomavirus infection 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
161 Human T-cell leukemia virus 1 infection 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
162 Human T-cell leukemia virus 1 infection 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
163 Huntington disease 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
164 Huntington disease 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
165 IgSF CAM signaling 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
166 IgSF CAM signaling 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
167 Inflammatory mediator regulation of TRP channels 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
168 Influenza A 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
169 Influenza A 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
170 Inositol phosphate metabolism 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
171 Insulin resistance 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
172 Insulin resistance 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
173 Insulin resistance 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
174 Insulin signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
175 Insulin signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
176 Insulin signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
177 Insulin signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
178 Integrated stress response (ISR) signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
179 Integrated stress response (ISR) signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
180 Integrin signaling 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
181 Integrin signaling 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
182 Integrin signaling 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
183 JAK-STAT signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
184 JAK-STAT signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
185 JAK-STAT signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
186 Kaposi sarcoma-associated herpesvirus infection 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
187 Kaposi sarcoma-associated herpesvirus infection 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
188 Kaposi sarcoma-associated herpesvirus infection 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
189 Kaposi sarcoma-associated herpesvirus infection 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
190 Leukocyte transendothelial migration 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
191 Lipid and atherosclerosis 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
192 Long-term depression 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
193 Long-term potentiation 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
194 Longevity regulating pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
195 Longevity regulating pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
196 Longevity regulating pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
197 Longevity regulating pathway - multiple species 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
198 Longevity regulating pathway - multiple species 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
199 Longevity regulating pathway - multiple species 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
200 Lysosome biogenesis 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
201 Lysosome biogenesis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
202 MAPK signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
203 Measles 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
204 Melanogenesis 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
205 Melanoma 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
206 Melanoma 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
207 MicroRNAs in cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
208 MicroRNAs in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
209 MicroRNAs in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
210 MicroRNAs in cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
211 mTOR signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
212 mTOR signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
213 mTOR signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
214 mTOR signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
215 Natural killer cell mediated cytotoxicity 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
216 Natural killer cell mediated cytotoxicity 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
217 Neuroactive ligand signaling 💬
[2] ADRB1, ADRB2 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
218 Neuroactive ligand signaling 💬
[2] ADRB1, ADRB2 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
219 Neuroactive ligand-receptor interaction 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
220 Neuroactive ligand-receptor interaction 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
221 Neurotrophin signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
222 Neurotrophin signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
223 Neutrophil extracellular trap formation 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
224 Neutrophil extracellular trap formation 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
225 Neutrophil extracellular trap formation 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
226 Neutrophil extracellular trap formation 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
227 Non-alcoholic fatty liver disease 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
228 Non-small cell lung cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
229 Non-small cell lung cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
230 Oocyte meiosis 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
231 Osteoclast differentiation 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
232 Osteoclast differentiation 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
233 Oxytocin signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
234 Pancreatic cancer 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
235 Pancreatic cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
236 Pancreatic cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
237 Pancreatic cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
238 Parathyroid hormone synthesis, secretion and action 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
239 Pathways in cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
240 Pathways in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
241 Pathways in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
242 Pathways in cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
243 Pathways of neurodegeneration - multiple diseases 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
244 Pathways of neurodegeneration - multiple diseases 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
245 Pathways of neurodegeneration - multiple diseases 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
246 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
247 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
248 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
249 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
250 Phagocytosis 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
251 Phosphatidylinositol signaling system 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
252 Phospholipase D signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
253 Phospholipase D signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
254 Phospholipase D signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
255 Phospholipase D signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
256 PI3K-Akt signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
257 PI3K-Akt signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
258 PI3K-Akt signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
259 PI3K-Akt signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
260 Platelet activation 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
261 Prion disease 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
262 Progesterone-mediated oocyte maturation 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
263 Progesterone-mediated oocyte maturation 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
264 Prolactin signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
265 Prolactin signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
266 Prostate cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
267 Prostate cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
268 Prostate cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
269 Prostate cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
270 Proteoglycans in cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
271 Proteoglycans in cancer 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
272 Proteoglycans in cancer 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
273 Proteoglycans in cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
274 Purine metabolism 💬
[1] PDE5A 💬 Sildenafil citrate 💬 Sildenafil [17]  6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬
275 Purine metabolism 💬
[1] PDE5A 💬 Sildenafil 💬 Sildenafil [17]  6 , 46, 50, 51, 85, 86, 90, 113, 210, 211, 212, 225, 226, 278, 294, 299, 301 💬
276 Rap1 signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
277 Rap1 signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
278 Ras signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
279 Ras signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
280 Regulation of actin cytoskeleton 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
281 Regulation of actin cytoskeleton 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
282 Regulation of lipolysis in adipocytes 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
283 Regulation of lipolysis in adipocytes 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
284 Regulation of lipolysis in adipocytes 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
285 Relaxin signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
286 Relaxin signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
287 Renal cell carcinoma 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
288 Renal cell carcinoma 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
289 Renin secretion 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
290 Renin secretion 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
291 Salivary secretion 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
292 Salivary secretion 💬
[3] ADRB1, ADRB2, ADRB3 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
293 Salmonella infection 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
294 Salmonella infection 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
295 Serotonergic synapse 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
296 Shigellosis 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
297 Shigellosis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
298 Shigellosis 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
299 Signaling pathways regulating pluripotency of stem cells 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
300 Signaling pathways regulating pluripotency of stem cells 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
301 Small cell lung cancer 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
302 Sphingolipid signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
303 Sphingolipid signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
304 Spinocerebellar ataxia 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
305 Spinocerebellar ataxia 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
306 Spinocerebellar ataxia 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
307 T cell receptor signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
308 T cell receptor signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
309 Th17 cell differentiation 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
310 Th17 cell differentiation 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
311 Thermogenesis 💬
[1] ADRB3 💬 Propranolol hydrochloride 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
312 Thermogenesis 💬
[1] ADRB3 💬 Propranolol 💬 Propranolol [7]  6 , 158, 167, 215, 216, 227, 278 💬
313 Thermogenesis 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
314 Thermogenesis 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
315 Thyroid cancer 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
316 Thyroid hormone signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
317 Thyroid hormone signaling pathway 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
318 Thyroid hormone signaling pathway 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
319 Thyroid hormone signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
320 TNF signaling pathway 💬
[1] MAP2K1 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
321 TNF signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
322 Toll-like receptor signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
323 Toll-like receptor signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
324 Type II diabetes mellitus 💬
[1] MTOR 💬 Everolimus 💬 Everolimus [12] 34, 67, 89, 96, 137, 157, 158, 228, 277, 278, 279, 280 💬
325 Type II diabetes mellitus 💬
[1] MTOR 💬 Sirolimus 💬 Sirolimus [46]  6 , 13, 15, 17, 19, 21, 34, 35, 36, 46, 48, 49, 51, 54, 57, 60, 61, 62, 63, 65, 66, 67, 84, 85, 86, 89, 97, 98, 111, 127, 137, 157, 158, 192, 222, 223, 227, 277, 278, 279, 280, 281, 283, 285, 300, 331 💬
326 Type II diabetes mellitus 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
327 Vascular smooth muscle contraction 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
328 VEGF signaling pathway 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
329 VEGF signaling pathway 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
330 Viral carcinogenesis 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬
331 Yersinia infection 💬
[2] MAP2K1, MAP2K2 💬 Mirdametinib 💬 Mirdametinib [4] 34, 278, 279, 280 💬
332 Yersinia infection 💬
[1] PIK3CA 💬 Alpelisib 💬 Alpelisib [4] 138, 278, 279, 280 💬